drugset
drugset / Trial / NCT05559359

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359 ↗

Phase 3 Active not recruiting 367 enrolled Eli Lilly and Company Dermira, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).

Timeline

Start
2022-10-18
Primary completion
2026-01-14
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lebrikizumab Monoclonal antibody — Subcutaneous

Indications

atopic eczema